Dimerix Limited announced that it has received ethics approvals for its DMX-200 Phase 2 clinical efficacy trials, enabling notification of the study commencement to the Australian TGA and patient recruitment to commence. Dimerix will now commence site initiation to enable recruitment of patients under the leadership of Principal Investigator, Professor Simon Roger, Director of Renal Research (private practice) in Gosford, New South Wales. Recruitment is on track to commence in third quarter of 2018 as forecast. The ethics approvals allow Dimerix to undertake two separate trials for patients with two indications of Chronic Kidney Disease (CKD): Focal Segmental Glomerulosclerosis (FSGS) and Diabetic Kidney Disease (DKD). These have been designed as randomised, double blind placebo-controlled, crossover studies, to maximise potential for data while being highly efficient and cost-effective. These two DMX-200 studies have been titled ACTION; they will investigate the AT1R and CCR2 Targets for Inflammatory Nephrosis. ACTION FOR FSGS: Phase 2a clinical trial will study the effects of DMX-200 in around 10 patients with FSGS ­ endpoints including safety and efficacy (proteinuria reduction). ACTION FOR DKD: Phase 2b clinical trial will study the effects of DMX-200 in around 40 patients with DKD ­ primary end point change in 24hr albumin creatinine ratio (ACR) based on identified patient responses in the previously conducted 2017 Phase 2a study. Each trial will test for safety and efficacy across the patient groups at around 10 identified clinical trial sites in Australia. Preliminary data is expected for both the DKD and FSGS studies in second half calendar year 2019.